Cetuximab (anti-EGFR monoclonal antibody) is thus far the only FDA approved drug available for use in relapsed or metastatic HNSCC—however it provides a low ORR of approximately 10% [33], likely due to multiple complex signaling pathways responsible for tumorigenesis besides EGFR, as well as high rates of acquired resistance [34]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.